LUYE PHARMA: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
LUYE PHARMA: NOTICE OF BOARD MEETING
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED FOR PHASE 3 CLINICAL STUDY OF THE GROUP''S INNOVATIVE FORMULATION LY01610
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - UPDATED PROGRESS IN RELATION TO THE MARKETING REVIEW OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) IN THE UNITED STATES
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING IN THE COMPANY BY CONTROLLING SHAREHOLDER
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE FORMULATIONS BAITUOWEI AND RYKINDO INCLUDED ON CHINA''S 2023 NATIONAL REIMBURSEMENT DRUG LIST
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG LURBINECTEDIN APPROVED FOR MARKETING IN HONG KONG
LUYE PHARMA: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
LUYE PHARMA: CHANGE OF NON-EXECUTIVE DIRECTOR
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - INNOVATIVE DRUG LURBINECTEDIN APPROVED FOR THE TREATMENT OF RELAPSED SMALL CELL LUNG CANCER IN MACAO, CHINA
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - RIVASTIGMINE TWICE WEEKLY TRANSDERMAL PATCH APPROVED FOR MARKETING IN CHINA
LUYE PHARMA: ANNOUNCEMENT IN RELATION TO THE 2022 ANNUAL REPORT
LUYE PHARMA: VOLUNTARY ANNOUNCEMENT - THE COMPANY SUBMITTED NDA FOR PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION (LY03010) TO THE FDA
LUYE PHARMA: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
LUYE PHARMA: Interim Report 2023
No Data